Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Whether working on dynamic discoveries in the lab, connecting with students and faculty or pursuing his passion for nature photography, acclaimed biomedical researcher John Kuriyan is inspired by his recent move to join Vanderbilt as the new dean of the School of Medicine Basic Sciences and Distinguished University Professor.

https://news.vanderbilt.edu/2023/04/03/new-dean-of-basic-sciences-aims-to-take-vanderbilt-to-the-next-level-in-biomedical-research-drug-discovery/

Mon, 04/03/2023 - 12:00

Cancer_Cell_Biology_Research_Program

Amy Wolf

Locked

Vanderbilt research presented at Cancer Moonshot meet

Vanderbilt Colorectal cancer expert Bob Coffey, MD, was recently invited to present his research to representatives of President Joe Bidenâ€™s reignited Cancer Moonshot initiative.

https://news.vumc.org/2023/12/08/vanderbilt-research-presented-at-cancer-moonshot-meet/

Fri, 12/08/2023 - 12:00

Gastrointestinal_Cancer_Research_Program

Bill Snyder

Locked

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

https://news.vumc.org/2023/10/04/vulnerability-found-in-immunotherapy-resistant-triple-negative-breast-cancer/

Wed, 10/04/2023 - 12:00

Breast_Cancer_Research_Program

Tom Wilemon

Locked

SPORE in Breast Cancer

SPORE in GI Cancer

Karen Winkfield named a fellow of the American Society for Radiation Oncology

Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, has been named a fellow of the American Society for Radiation Oncology.

https://news.vumc.org/2023/08/01/karen-winkfield-named-a-fellow-of-the-american-society-for-radiation-oncology/

Tue, 08/01/2023 - 12:00

Cancer_Health_Outcomes_and_Control_Research_Program

Tom Wilemon

Locked

Study finds new genetic susceptibilities for colon cancer

Vanderbilt researchers at have found new genes that put people at higher risk for colon cancer and rectal cancer.

https://news.vumc.org/2023/09/12/study-finds-new-genetic-susceptibilities-for-colon-cancer/

Tue, 09/12/2023 - 12:00

Cancer_Epidemiology_Research_Program

Tom Wilemon

Locked

Breast

Persons with secondary arm and/or upper quadrant lymphedema following cancer therapies commonly are prescribed complete decongestive therapy as a course of management of their lymphedema. The investigators will perform a repeated-measures cross-over trial to test the hypothesis that mobilization of protein enriched hardened tissue using graded negative pressure therapy in conjunction with complete decongestive therapy (CDT) is more effective to standard CDT alone for secondary lymphedema management.

Disease Sites: Breast

Phase: N/A

Investigator: Donahue, Manus

NCTID: NCT03760744

Protocol No: VICCBRE18156

Learn More

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Multiple Myeloma

The purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.

Disease Sites: Multiple Myeloma

Phase: N/A

Investigator: Oluwole, Olalekan

NCTID: NCT05346835

Protocol No: VICC-XDCTT24033

Learn More

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Breast

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Disease Sites: Breast

Phase: III

Investigator: Abramson, Vandana

NCTID: NCT06492616

Protocol No: VICC-DTBRE24171

Learn More

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Vanderbilt research presented at Cancer Moonshot meet